AstraZeneca says its coronavirus vaccine triggers immune response among adults
- British pharmaceutical giant AstraZeneca said its Covid-19 vaccine candidate has produced a similar immune response in older and younger adults.
- AstraZeneca, which is developing its vaccine in collaboration with the University of Oxford, said adverse responses to the vaccine among the elderly were also found to be lower.
LONDON — British pharmaceutical giant AstraZeneca on Monday said its potential Covid-19 vaccine has produced a similar immune response in older and younger adults.
AstraZeneca, which is developing its potential Covid-19 vaccine in collaboration with the University of Oxford, said adverse responses to the vaccine among the elderly were also found to be lower.
The World Health Organization has said that older people, in addition to people of all ages with preexisting medical conditions, appear to develop serious illness on contracting the coronavirus more often than others.
The announcement is likely to boost hopes of a Covid vaccine being developed before the end of the year.
"It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher," an AstraZeneca spokesman told CNBC via email.
"The results further build the body of evidence for the safety and immunogenicity of AZD1222," the spokesman said, referring to the technical name of the Oxford-AstraZeneca vaccine.
Shares of the company rose more than 2% on the news.
Drugmakers and research centers are scrambling to deliver a safe and effective vaccine in an attempt to bring an end to the coronavirus pandemic that has claimed over 1.15 million lives.
Dozens of candidate vaccines are in clinical evaluation, according to the WHO, with some already conducting late-stage tests before seeking formal approval.
The vaccine being developed by the University of Oxford and AstraZeneca is thought to be one of the frontrunners to secure regulatory approval.
AstraZeneca CEO Pascal Soirot has previously said the drugmaker's vaccine would likely provide protection against contracting the coronavirus for about a year.